Jonathan (John) Finn, Ph.D., is the Chief Scientific Officer at Basecamp Research, where he leads efforts to develop programmable genetic medicines. With a strong background in gene therapy, Finn previously worked at Tome Biosciences, where he focused on solving complex genetic engineering challenges. At Basecamp, he is advancing the use of large serine recombinases (LSRs), a promising alternative to CRISPR, capable of inserting large DNA sequences directly into specific genome sites. His work supports Basecamp’s mission to revolutionize biological design using AI and vast genomic datasets.